These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16711515)

  • 61. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review.
    Yashi M; Terauchi F; Nukui A; Ochi M; Yuzawa M; Hara Y; Morita T
    Urol Oncol; 2006; 24(4):313-7. PubMed ID: 16818183
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate.
    Schmid KW; Helpap B; Tötsch M; Kirchmair R; Dockhorn-Dworniczak B; Böcker W; Fischer-Colbrie R
    Histopathology; 1994 Mar; 24(3):233-9. PubMed ID: 7515371
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
    Lissoni P; Cazzaniga M; Tancini G; Scardino E; Musci R; Barni S; Maffezzini M; Meroni T; Rocco F; Conti A; Maestroni G
    Eur Urol; 1997; 31(2):178-81. PubMed ID: 9076462
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Variation of chromogranin A serum levels after radical retropubic prostatectomy for prostate adenocarcinoma.
    Sciarra A; Gentile V; Monti S; Mariotti G; Pastore A; Di Silverio F
    Arch Androl; 2003; 49(1):39-48. PubMed ID: 12647777
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.
    Bollito E; Berruti A; Bellina M; Mosca A; Leonardo E; Tarabuzzi R; Cappia S; Ari MM; Tampellini M; Fontana D; Gubetta L; Angeli A; Dogliotti L
    Ann Oncol; 2001; 12 Suppl 2():S159-64. PubMed ID: 11762345
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer.
    Furuya Y; Nozaki T; Nagakawa O; Fuse H
    Endocr J; 2002 Feb; 49(1):85-90. PubMed ID: 12008754
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Chromogranin A, chromogranin B, chromogranin C].
    Takekoshi K
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():407-10. PubMed ID: 16149541
    [No Abstract]   [Full Text] [Related]  

  • 68. Androgen, estrogen, and progesterone receptor contents and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate.
    Kumar VL; Wadhwa SN; Kumar V; Farooq A
    J Surg Oncol; 1990 Jun; 44(2):122-8. PubMed ID: 1693995
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Chromogranin A--serum marker for prostate cancer.
    Khan MO; Ather MH
    J Pak Med Assoc; 2011 Jan; 61(1):108-11. PubMed ID: 22368921
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
    Lissoni P; Malugani F; Casu M; Bukovec R; Egardi R; Bordin V; Fumagalli E; Mengo S; Gardani G
    Neuro Endocrinol Lett; 2002 Feb; 23(1):61-3. PubMed ID: 11880864
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Implications of circulating chromogranin A in prostate cancer.
    Hirano D; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Kawata N; Yoshida T; Takahashi S
    Scand J Urol Nephrol; 2007; 41(4):297-301. PubMed ID: 17763220
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
    Redding TW; Schally AV
    Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
    Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
    Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis.
    Borch K; Stridsberg M; Burman P; Rehfeld JF
    Scand J Gastroenterol; 1997 Mar; 32(3):198-202. PubMed ID: 9085454
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Chromogranin A, chromogranin B, chromogranin C].
    Takekoshi K; Nakai T; Matsui Y
    Nihon Rinsho; 1999 Dec; 57 Suppl():234-7. PubMed ID: 10778109
    [No Abstract]   [Full Text] [Related]  

  • 76. Prolactin and prostate: a chronobiologic study.
    Selli C; Benvenuti M; Melone F; Romano S; Tarquini B
    Eur Urol; 1983; 9(2):109-12. PubMed ID: 6189717
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Castration refractory prostate cancer: cinderella finally comes to the ball.
    Chowdhury S; Harper P; Powles T
    Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
    [No Abstract]   [Full Text] [Related]  

  • 78. Investigative clinical study on prostate cancer part VII: prolactin and the pituitary-testis-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
    Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
    Anticancer Res; 2011 Nov; 31(11):3913-20. PubMed ID: 22110219
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones.
    Kimura N; Miura W; Noshiro T; Mizunashi K; Hanew K; Shimizu K; Watanabe T; Shibukawa S; Sohn HE; Abe K; Miura Y; Nagura H
    Endocr J; 1997 Apr; 44(2):319-27. PubMed ID: 9228469
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
    Casella R; Bubendorf L; Sauter G; Moch H; Mihatsch MJ; Gasser TC
    J Urol; 1998 Aug; 160(2):406-10. PubMed ID: 9679888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.